Fortis Therapeutics is developing novel antibody-drug conjugates (ADCs) against CD46, an immune modulatory receptor that is highly expressed in multiple tumor types.  They have initiated clinical trials for metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The company was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.